R. D. Schreiber, L. J. Old, and M. J. Smyth, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, 2011.

M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, vol.29, pp.235-71, 2011.

S. Z. Josefowicz, L. F. Lu, and A. Y. Rudensky, Regulatory T cells: mechanisms of differentiation and function, Annu Rev Immunol, vol.30, pp.531-64, 2012.

A. Schmidt, N. Oberle, and P. H. Krammer, Molecular mechanisms of tregmediated T cell suppression, Front Immunol, vol.3, p.51, 2012.

J. B. Wing and S. Sakaguchi, Multiple treg suppressive modules and their adaptability, Front Immunol, vol.3, p.178, 2012.

C. M. Wilke, K. Wu, E. Zhao, G. Wang, and W. Zou, Prognostic significance of regulatory T cells in tumor, Int J Cancer, vol.127, pp.748-58, 2010.

C. Menetrier-caux, M. Gobert, and C. Caux, Differences in tumor regulatory T-cell localization and activation status impact patient outcome, Cancer Res, vol.69, pp.7895-7903, 2009.

P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps et al., Tumor-infiltrating FOXP3C T regulatory cells show strong prognostic significance in colorectal cancer, J Clin Oncol, vol.27, pp.186-92, 2009.

A. Tzankov, C. Meier, P. Hirschmann, P. Went, S. A. Pileri et al., Correlation of high numbers of intratumoral FOXP3C regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma, Haematologica, vol.93, pp.193-200, 2008.

T. J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, vol.10, pp.942-951, 2004.

Q. Gao, S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang et al., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection, J Clin Oncol, vol.25, pp.2586-93, 2007.

N. Kobayashi, N. Hiraoka, W. Yamagami, H. Ojima, Y. Kanai et al., FOXP3C regulatory T cells affect the development and progression of hepatocarcinogenesis, Clin Cancer Res, vol.13, pp.902-913, 2007.

Y. Mizukami, K. Kono, Y. Kawaguchi, H. Akaike, K. Kamimura et al., Localisation pattern of Foxp3C regulatory T cells is associated with clinical behaviour in gastric cancer, Br J Cancer, vol.98, pp.148-53, 2008.

R. P. Petersen, M. J. Campa, J. Sperlazza, D. Conlon, M. B. Joshi et al., Tumor infiltrating Foxp3C regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, vol.107, pp.2866-72, 2006.

S. H. Van-der-burg, S. J. Piersma, A. De-jong, J. M. Van-der-hulst, K. M. Kwappenberg et al., Association of cervical cancer with the presence of CD4C regulatory T cells specific for human papillomavirus antigens, Proc Natl Acad Sci, vol.104, pp.12087-92, 2007.

K. Munger, The role of human papillomaviruses in human cancers, Front Biosci, vol.7, pp.641-650, 2002.

N. Chaoul, C. Fayolle, B. Desrues, M. Oberkampf, A. Tang et al., Rapamycin impairs antitumor CD8C T-cell responses and vaccine-induced tumor eradication, Cancer Res, vol.75, pp.3279-91, 2015.

P. Berraondo, C. Nouze, X. Preville, D. Ladant, and C. Leclerc, Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system, Cancer Res, vol.67, pp.8847-55, 2007.

A. Sainz-perez, A. Lim, B. Lemercier, and C. Leclerc, The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences, Cancer Res, vol.72, pp.3557-69, 2012.

M. J. Grusby, R. S. Johnson, V. E. Papaioannou, and L. H. Glimcher, Depletion of CD4C T cells in major histocompatibility complex class II-deficient mice, Science, vol.253, pp.1417-1437, 1991.

D. D. Kish, A. V. Gorbachev, and R. L. Fairchild, Regulatory function of CD4CCD25C T cells from Class II MHC-deficient mice in contact hypersensitivity responses, J Leukocyte Biol, vol.82, pp.85-92, 2007.

P. Bochtler, C. Wahl, R. Schirmbeck, and J. Reimann, Functional adaptive CD4 Foxp3 T cells develop in MHC class II-deficient mice, J Immunol, vol.177, pp.8307-8321, 2006.

D. Anz, W. Mueller, M. Golic, W. G. Kunz, M. Rapp et al., CD103 is a hallmark of tumor-infiltrating regulatory T cells, Int J Cancer, vol.129, pp.2417-2443, 2011.

A. E. Herman, G. J. Freeman, D. Mathis, and C. Benoist, CD4CCD25C T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion, J Exp Med, vol.199, pp.1479-89, 2004.

M. Vocanson, A. Rozieres, A. Hennino, G. Poyet, V. Gaillard et al., Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells, J Allergy Clin Immunol, vol.126, pp.1-7, 2010.

M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, vol.26, pp.677-704, 2008.

L. Shi, S. Chen, L. Yang, and Y. Li, The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies, J Hematol Oncol, vol.6, p.74, 2013.

J. M. Weiss, A. M. Bilate, M. Gobert, Y. Ding, C. De-lafaille et al., Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3C T reg cells, J Exp Med, vol.209, pp.1723-1765, 2012.

M. Yadav, C. Louvet, D. Davini, J. M. Gardner, M. Martinez-llordella et al., Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo, J Exp Med, vol.209, pp.1713-1735, 2012.

P. Milpied, A. Renand, J. Bruneau, D. A. Mendes-da-cruz, J. S. Asnafi et al., Neuropilin-1 is not a marker of human Foxp3C Treg, Eur J Immunol, vol.39, pp.1466-71, 2009.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Eng J Med, vol.366, pp.2443-54, 2012.

L. Madsen, N. Labrecque, J. Engberg, A. Dierich, A. Svejgaard et al., Mice lacking all conventional MHC class II genes, Proc Natl Acad Sci U S A, vol.96, pp.10338-10381, 1999.

B. Jaron, E. Maranghi, C. Leclerc, and L. Majlessi, Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis, PLoS One, vol.3, p.2833, 2008.

P. E. Fecci, A. E. Sweeney, P. M. Grossi, S. K. Nair, C. A. Learn et al., Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells, Clin Cancer Res, vol.12, pp.4294-305, 2006.

F. Moschella, G. F. Torelli, M. Valentini, F. Urbani, C. Buccione et al., Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy, Clin Cancer Res, vol.19, pp.4249-61, 2013.

G. Schiavoni, F. Mattei, D. Pucchio, T. Santini, S. M. Bracci et al., Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer, Blood, vol.95, pp.2024-2054, 2000.

G. Schiavoni, A. Sistigu, M. Valentini, F. Mattei, P. Sestili et al., Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis, Cancer Res, vol.71, pp.768-78, 2011.

F. Ghiringhelli, C. Menard, P. E. Puig, S. Ladoire, S. Roux et al., Metronomic cyclophosphamide regimen selectively depletes CD4CCD25C regulatory T cells and restores T and NK effector functions in end stage cancer patients, Cancer Immunol Immunother, vol.56, pp.641-649, 2007.

M. Bruchard, G. Mignot, V. Derangere, F. Chalmin, A. Chevriaux et al., Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth, Nat Med, vol.19, pp.57-64, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00919371

R. A. Lake and B. W. Robinson, Immunotherapy and chemotherapy-a practical partnership, Nat Rev Cancer, vol.5, pp.397-405, 2005.

Y. Ma, S. Adjemian, S. R. Mattarollo, T. Yamazaki, L. Aymeric et al., Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells, Immunity, vol.38, pp.729-770, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02047416

Y. Ma, S. Adjemian, H. Yang, J. P. Catani, D. Hannani et al., ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy, Oncoimmunology, vol.2, p.24568, 2013.
URL : https://hal.archives-ouvertes.fr/hal-02047415

E. Vacchelli, I. Vitale, E. Tartour, A. Eggermont, C. Sautes-fridman et al., Combining immunotherapy with chemotherapy to treat cancer, Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology, vol.2, pp.265-70, 2005.

G. Bindea, B. Mlecnik, M. Tosolini, A. Kirilovsky, M. Waldner et al., Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer, Immunity, vol.39, pp.782-95, 2013.

K. Hiraoka, M. Miyamoto, Y. Cho, M. Suzuoki, T. Oshikiri et al., Concurrent infiltration by CD8C T cells and CD4C T cells is a favourable prognostic factor in non-small-cell lung carcinoma, Br J Cancer, vol.94, pp.275-80, 2006.

F. Pages, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector memory T cells, early metastasis, and survival in colorectal cancer, N Engl J Med, vol.353, pp.2654-66, 2005.

F. Pages, J. Galon, and W. H. Fridman, The essential role of the in situ immune reaction in human colorectal cancer, J Leukocyte Biol, vol.84, pp.981-988, 2008.

M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, S. Mauger et al., Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res, vol.71, pp.1263-71, 2011.

D. I. Gabrilovich, S. Ostrand-rosenberg, and V. Bronte, Coordinated regulation of myeloid cells by tumours, Nat Rev Immunol, vol.12, pp.253-68, 2012.

N. Chaput, G. Darrasse-jeze, A. S. Bergot, C. Cordier, S. Ngo-abdalla et al., Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites, J Immunol, vol.179, pp.4969-78, 2007.

D. Daniel, N. Meyer-morse, E. K. Bergsland, K. Dehne, L. M. Coussens et al., Immune enhancement of skin carcinogenesis by CD4C T cells, J Exp Med, vol.197, pp.1017-1045, 2003.

M. Zabala, J. J. Lasarte, C. Perret, J. Sola, P. Berraondo et al., Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer, J Hepatol, vol.47, pp.807-822, 2007.

M. Mkrtichyan, Y. G. Najjar, E. C. Raulfs, M. Y. Abdalla, R. Samara et al., Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms, Eur J Immunol, vol.41, pp.2977-86, 2011.

Z. Liu, H. Zhou, W. Wang, Y. X. Fu, and M. Zhu, A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice, Oncoimmunology, vol.5, p.1147641, 2016.

A. Tang, G. Dadaglio, M. Oberkampf, D. Carlo, S. Peduto et al., B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer, Int J Cancer, vol.139, pp.1358-71, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-01942430

S. Koyama, E. A. Akbay, Y. Y. Li, G. S. Herter-sprie, K. A. Buczkowski et al., Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat Commun, vol.7, p.10501, 2016.

R. Y. Huang, A. Francois, A. R. Mcgray, A. Miliotto, and K. Odunsi, Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer, Oncoimmunology, vol.6, p.1249561, 2017.

W. W. Agace, J. M. Higgins, B. Sadasivan, M. B. Brenner, and C. M. Parker, Tlymphocyte-epithelial-cell interactions: integrin alpha(E)(CD103)beta (7), LEEP-CAM and chemokines, Curr Opin Cell Biol, vol.12, pp.563-571, 2000.

S. Dadi, S. Chhangawala, B. M. Whitlock, R. A. Franklin, C. T. Luo et al., Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells, Cell, vol.164, pp.365-77, 2016.

M. Nizard, H. Roussel, M. O. Diniz, S. Karaki, T. Tran et al., Induction of resident memory T cells enhances the efficacy of cancer vaccine, Nat Commun, vol.8, p.15221, 2017.

M. A. Koch, K. R. Thomas, N. R. Perdue, K. S. Smigiel, S. Srivastava et al., T-bet(C) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor beta2, Immunity, vol.37, pp.501-511, 2012.

M. A. Koch, G. Tucker-heard, N. R. Perdue, J. R. Killebrew, K. B. Urdahl et al., The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation, Nat Immunol, vol.10, pp.595-602, 2009.

F. Yu, S. Sharma, J. Edwards, L. Feigenbaum, and J. Zhu, Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance, Nat Immunol, vol.16, pp.197-206, 2015.

D. L. Clouthier, A. C. Zhou, and T. H. Watts, Anti-GITR agonist therapy intrinsically enhances CD8 T cell responses to chronic lymphocytic choriomeningitis virus (LCMV), thereby circumventing LCMV-induced downregulation of costimulatory GITR ligand on APC, J Immunol, vol.193, pp.5033-5076, 2014.

J. J. Wallin, L. Liang, A. Bakardjiev, and W. C. Sha, Enhancement of CD8C T cell responses by ICOS/B7 h costimulation, J Immunol, vol.167, pp.132-141, 2001.

P. Guermonprez, C. Fayolle, M. J. Rojas, M. Rescigno, D. Ladant et al., In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11 c C CD8 alpha -CD11bhigh dendritic cells, Eur J Immunol, vol.32, pp.3071-81, 2002.

Y. Wang, A. Kissenpfennig, M. Mingueneau, S. Richelme, P. Perrin et al., Th2 lymphoproliferative disorder of LatY136 F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3C regulatory T cells, J Immunol, vol.180, pp.1565-75, 2008.

K. Y. Lin, F. G. Guarnieri, -. Staveley, K. F. Carroll, H. I. Levitsky et al., Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen, Cancer Res, vol.56, pp.21-27, 1996.

X. Preville, D. Ladant, B. Timmerman, and C. Leclerc, Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein, Cancer Res, vol.65, pp.641-650, 2005.